Back to Search Results
Study Complete
Sponsor ID
20120139

Registry Study for talimogene laherparepvec

Sponsor ID
20120139
Clinicaltrials.gov ID
NCT02173171
EUCTIS ID
N/A
EudraCT ID
N/A
Contact Us

Study Details

A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials

Additional Study Details

Phase
N/A
Product
talimogene laherparepvec (T-VEC)
Type
Observational
Masking
N/A
Enrollment
185
Additional Study Details

Protocol Summary

Primary Outcome Measures

Talimogene Laherparepvec Related Adverse Events

Timeframe: 7 years

Subject overall survival

Timeframe: 7 years

Use of subsequent anti-cancer therapy

Timeframe: 7 years

Secondary Outcome Measures
Not Available

Locations

Location
Status
Contact Us
Location
Investigative Clinical Research of Indiana, LLC
Indianapolis, IN, United States, 46260
Status
Recruiting
Location
Baptist MD Anderson Cancer Center
Jacksonville, FL, United States, 32207
Status
Recruiting
Location
Wilgers Oncology Centre
Pretoria, South Africa, 0081
Status
Recruiting
Location
The West Clinic PC dba West Cancer Center
Germantown, TN, United States, 38138
Status
Terminated
Location
Gabrail Cancer Center, LLC
Canton, OH, United States, 44718
Status
Terminated
Location
Intermountain Medical Center
Murray, UT, United States, 84107
Status
Recruiting
Showing {first} - {last} of {total} Results
Study Info
Age
18 - 99 Years
Condition
  • Tumor
    • Sex
    All
    Trial Dates
    Apr 2010 - Sep 2021
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    All subjects must provide informed consent prior to initiation of any study activities. All subjects must have received at least one dose of talimogene laherparepvec on an Amgen or BioVEX-sponsored clinical trial for any tumor type and must have discontinued treatment and participation, including long-term follow-up (if applicable) in that trial.
    Exclusion Criteria:
    Subjects currently receiving talimogene laherparepvec in Amgen or BioVEX-sponsored clinical trial. Subject currently participating, including for long-term follow-up (if applicable), in other Amgen-sponsored talimogene laherparepvec clinical trial.